Kehoe S
Department of Obstetrics and Gynaecology, City Hospital Trust, Birmingham.
Hosp Med. 1998 Jun;59(6):442-6.
Although survival in ovarian cancer remains poor, the use of paclitaxel and interval debulking surgery are now recognized to prolong survival. Future trials addressing the role of surgery, novel applications of chemotherapy, and screening, along with care by recognized specialists, may well improve outcome.
尽管卵巢癌患者的生存率仍然很低,但目前已认识到使用紫杉醇和间歇性肿瘤细胞减灭术可延长生存期。未来针对手术作用、化疗新应用和筛查的试验,以及由知名专家进行的治疗,很可能会改善治疗结果。